This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Tohru Kiyono: Innovator in Hepatic and Intestinal Cell Research
Introduction
Tohru Kiyono is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cellular biology, particularly in the preparation of functional hepatic and intestinal epithelial progenitor cells. His innovative methods have the potential to advance research in regenerative medicine and therapeutic applications.
Latest Patents
Tohru Kiyono holds a patent for a method for preparing functional hepatic progenitor cells or small intestinal epithelial progenitor cells. This method involves culturing an isolated cell population in the presence of an antibiotic. The patent also describes a substantially homogeneous isolated cell population comprising functional hepatic progenitor cells, which exhibit an increased expression level of CYP3A4, at least five times higher than that in a HepaRG® cell line. This innovation is crucial for enhancing the efficiency of cell-based therapies.
Career Highlights
Throughout his career, Tohru Kiyono has focused on the intersection of cellular biology and therapeutic applications. His work has been instrumental in developing methods that improve the viability and functionality of progenitor cells. His dedication to research has positioned him as a key figure in the scientific community.
Collaborations
Tohru Kiyono has collaborated with various researchers, including Akihiro Umezawa. These partnerships have fostered advancements in their respective fields and have contributed to the development of innovative methodologies in cell preparation.
Conclusion
Tohru Kiyono's contributions to the field of cellular biology, particularly through his patented methods, highlight his role as an innovator. His work continues to influence research in regenerative medicine and cell therapy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile